NEUROLOGY 1996;46:538-545
© 1996 American Academy of Neurology
Immunoglobulins reactive with myelin basic protein promote CNS remyelination
Moses Rodriguez, MD,
David J. Miller, PhD and
Vanda A. Lennon, MD, PhD
From the Departments of Neurology (Drs. Rodriguez and Lennon), Immunology (Drs. Rodriguez, Miller, and Lennon), and Laboratory Medicine and Pathology (Dr. Lennon), Mayo Medical School, Rochester, MN.
Supported by research grants NS 24180 from the National Institutes of Health, and RG 1878-B1 and RG 2174-A-3 from the National Multiple Sclerosis Society, and the C.T. Fernie Fund.
Received March 10, 1995 Accepted in final form April 26, 1995.
Address correspondence and reprint requests to Dr. Moses Rodriguez, Department of Immunology, Mayo Clinic/Foundation, Rochester, MN 55905.
We tested the hypothesis that immunoglobulins directed against a CNS autoantigen, myelin basic protein, may promote remyelination in the course of a chronic, immune-mediated demyelinating disease SJL/J mice infected chronically with Daniel's strain of Theiler's virus served as an experimental model of MS. The spinal cords of these mice exhibit extensive primary demyelination and inflammation with minimal spontaneous remyelination. Treatment with whole antiserum or affinity-purified mouse immunoglobulins directed against rat or rabbit myelin basic protein increased new myelin synthesis as measured by quantitative morphometry. Electron microscopy revealed numerous oligodendrocytes in remyelinated CNS lesions and a relative lack of inflammatory cells. Viral antigen persisted in the spinal cord despite enhanced CNS-type remyelination. These findings indicate that immunoglobulins reactive with myelin autoantigens have the potential to promote myelin repair.
NEUROLOGY 1996;46: 538-545
This article has been cited by other articles:
|
|
|
|
 
D. Pohlau, H. Przuntek, M. Sailer, F. Bethke, J. Koehler, N. Konig, C. Heesen, P. Spath, and I. Andresen
Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study
Multiple Sclerosis,
November 1, 2007;
13(9):
1107 - 1117.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Blanchette
Clinical significance of glatiramer acetate antibodies
Multiple Sclerosis,
May 1, 2007;
13(1_suppl):
28 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. H. Noseworthy, P. C. O'Brien, T. M. Petterson, J. Weis, L. Stevens, W. K. Peterson, D. Sneve, S. A. Cross, J. A. Leavitt, R. G. Auger, et al.
A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis
Neurology,
June 12, 2001;
56(11):
1514 - 1522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. H. Noseworthy, P. C. O'Brien, B. G. Weinshenker, J. A. Weis, T. M. Petterson, B. J. Erickson, A. J. Windebank, J. P. Whisnant, K. A. Stolp-Smith, C. M. Harper Jr., et al.
IV immunoglobulin does not reverse established weakness in MS: A double-blind, placebo-controlled trial
Neurology,
October 24, 2000;
55(8):
1135 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stangel, F. Boegner, C. H Klatt, C. Hofmeister, and S. Seyfert
Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis
J. Neurol. Neurosurg. Psychiatry,
January 1, 2000;
68(1):
89 - 92.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Mata, F. Lolli, M. Soderstrom, F. Pinto, and H. Link
Multiple sclerosis is associated with enhanced B cell responses to the ganglioside GD I a
Multiple Sclerosis,
December 1, 1999;
5(6):
379 - 388.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. J.M. Franklin
Review : Remyelination--A Regenerative Process in the CNS
Neuroscientist,
May 1, 1999;
5(3):
184 - 191.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. F Smith and C. L Darlington
Recent developments in drug therapy for multiple sclerosis
Multiple Sclerosis,
April 1, 1999;
5(2):
110 - 120.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Mcgavern, K. Asakura, and M. Rodriquez
Do Antibodies Stimulate Myelin Repair in Multiple Sclerosis?
Neuroscientist,
January 1, 1999;
5(1):
19 - 28.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Asakura, D. J. Miller, L. R. Pease, and M. Rodriguez
Targeting of IgMkappa Antibodies to Oligodendrocytes Promotes CNS Remyelination
J. Neurosci.,
October 1, 1998;
18(19):
7700 - 7708.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Asakura and M Rodriguez
A unique population of circulating autoantibodies promotes central nervous system remyelination
Multiple Sclerosis,
June 1, 1998;
4(3):
217 - 221.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. S Francis, M. S Freedman, and J. P Antel
Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study
Multiple Sclerosis,
December 1, 1997;
3(6):
370 - 376.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. Fazekas, F. Deisenhammer, S. Strasser-Fuchs, G. Nahler, and B. Mamoli for the Au
Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study
Multiple Sclerosis,
April 1, 1997;
3(2):
137 - 141.
[Abstract]
[PDF]
|
|
|
|
